Invesaro

Stocks Comparison

Myriad Genetics vs QuidelOrtho: revenue, profit, margins and growth compared

Myriad Genetics brought in $824.5M of revenue in fiscal 2025, QuidelOrtho $2.7B in fiscal 2025. Revenue changed by -1.6% at Myriad Genetics and -1.9% at QuidelOrtho on the year before, so Myriad Genetics grew faster. Myriad Genetics kept -44.4% of its revenue as net profit, QuidelOrtho -41.5%.

Side by side, latest fiscal year

MYGNQDEL
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 28, 2025)
Revenue$824.5M$2.7B
Revenue growth-1.6%-1.9%
Net income-$365.9M-$1.1B
Net margin-44.4%-41.5%
Free cash flown/a-$83M
Free cash flow marginn/a-3.0%
Earnings per share (diluted)-$3.95-$16.69
Cash$149.6M$169.8M
Debt$119.9M$2.7B
Price to earningsn/an/a
Market value$398.9M$750.2M
Dividend yieldn/an/a
Rank by revenue in sector#159 of 523 · Health care#90 of 523 · Health care

Over the years

Revenue
MYGN FY2019: $851.1MMYGN FY2020: $638.6MMYGN FY2020: $557.1MMYGN FY2021: $690.6MMYGN FY2022: $678.4MMYGN FY2023: $753.2MMYGN FY2024: $837.6MMYGN FY2025: $824.5MQDEL FY2020: $1.7BQDEL FY2022: $1.7BQDEL FY2022: $3.3BQDEL FY2023: $3BQDEL FY2024: $2.8BQDEL FY2025: $2.7BFY19FY20FY21FY22FY23FY24FY25
MYGN $824.5MQDEL $2.7B
Net income
MYGN FY2019: $4.6MMYGN FY2020: -$199.5MMYGN FY2020: -$223.6MMYGN FY2021: -$27.2MMYGN FY2022: -$112MMYGN FY2023: -$263.3MMYGN FY2024: -$127.3MMYGN FY2025: -$365.9MQDEL FY2020: $810.3MQDEL FY2022: $704.2MQDEL FY2022: $548.7MQDEL FY2023: -$10.1MQDEL FY2024: -$2.1BQDEL FY2025: -$1.1BFY19FY20FY21FY22FY23FY24FY25
MYGN -$365.9MQDEL -$1.1B
Net margin
MYGN FY2019: 0.5%MYGN FY2020: -31.2%MYGN FY2020: -40.1%MYGN FY2021: -3.9%MYGN FY2022: -16.5%MYGN FY2023: -35.0%MYGN FY2024: -15.2%MYGN FY2025: -44.4%QDEL FY2020: 48.8%QDEL FY2022: 41.5%QDEL FY2022: 16.8%QDEL FY2023: -0.3%QDEL FY2024: -73.7%QDEL FY2025: -41.5%FY19FY20FY21FY22FY23FY24FY25
MYGN -44.4%QDEL -41.5%
Revenue growth
MYGN FY2020: -25.0%MYGN FY2020: -12.8%MYGN FY2021: +24.0%MYGN FY2022: -1.8%MYGN FY2023: +11.0%MYGN FY2024: +11.2%MYGN FY2025: -1.6%QDEL FY2022: +2.2%QDEL FY2022: +92.3%QDEL FY2023: -8.2%QDEL FY2024: -7.2%QDEL FY2025: -1.9%FY20FY21FY22FY23FY24FY25
MYGN -1.6%QDEL -1.9%
Free cash flow
MYGN FY2019: $75.1MMYGN FY2020: $50.5MMYGN FY2021: $600KMYGN FY2022: -$151.6MQDEL FY2020: $564.8MQDEL FY2022: $513.1MQDEL FY2022: $744.4MQDEL FY2023: $70.9MQDEL FY2024: -$112.1MQDEL FY2025: -$83MFY19FY20FY21FY22FY23FY24FY25
MYGN -$151.6MQDEL -$83M

Fiscal years as each company reports them; the two may end in different months.

Questions about Myriad Genetics and QuidelOrtho

Which is bigger by revenue, Myriad Genetics or QuidelOrtho?

QuidelOrtho is bigger by revenue: $2.7B in fiscal 2025, against $824.5M for Myriad Genetics in fiscal 2025.

Which keeps more of its revenue as profit, Myriad Genetics or QuidelOrtho?

Myriad Genetics had a net margin of -44.4% in fiscal 2025; QuidelOrtho had -41.5% in fiscal 2025.

Which grew revenue faster, Myriad Genetics or QuidelOrtho?

In their latest fiscal years revenue changed by -1.6% at Myriad Genetics and -1.9% at QuidelOrtho.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies